BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Burkett BJ, Dundar A, Young JR, Packard AT, Johnson GB, Halfdanarson TR, Eiring RA, Gansen DN, Patton CM, Kendi AT. How We Do It: A Multidisciplinary Approach to 177Lu DOTATATE Peptide Receptor Radionuclide Therapy. Radiology 2021;298:261-74. [PMID: 33231532 DOI: 10.1148/radiol.2020201745] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
Number Citing Articles
1 Prado-Wohlwend S, Bernal-Vergara JC, Utrera-Costero A, Cañón-Sánchez JR, Agudelo-Cifuentes M, Bello-Arques P; Endocrinology Working Group of the SEMNIM. Peptide receptor radionuclide therapy with [177Lu]Lu-DOTA-TATE. Rev Esp Med Nucl Imagen Mol (Engl Ed) 2021:S2253-8089(21)00164-6. [PMID: 34920969 DOI: 10.1016/j.remnie.2021.11.001] [Reference Citation Analysis]
2 Calabrò D, Argalia G, Ambrosini V. Role of PET/CT and Therapy Management of Pancreatic Neuroendocrine Tumors.Diagnostics (Basel). 2020;10. [PMID: 33297381 DOI: 10.3390/diagnostics10121059] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
3 Rowe SP, Pomper MG. Molecular imaging in oncology: Current impact and future directions. CA Cancer J Clin 2021. [PMID: 34902160 DOI: 10.3322/caac.21713] [Reference Citation Analysis]
4 Roseland ME, Francis IR, Shampain KL, Stein EB, Wasnik AP, Millet JD. Gastric neuroendocrine neoplasms: a primer for radiologists. Abdom Radiol (NY) 2022. [PMID: 35411433 DOI: 10.1007/s00261-022-03509-1] [Reference Citation Analysis]